Prof Gnant speaks at a SABCS 2017 press session about data from the ABCSG-16 phase III trial.

Postmenopausal women with hormone-receptor positive (HR-positive) breast cancer who took the aromatase inhibitor anastrozole for two years after an initial five years of adjuvant endocrine therapy received an equal benefit to those who took the drug for five additional years.

The trial results suggest that a shorter duration of treatment may provide sufficient benefits while protecting women from harmful side effects.

Read the news story for more.